SPDR S&P Biotech ETF (XBI)
| 109.76 Data as of 3:59pm ET |  +1.07 / +0.98%Today’s Change | 77.00 Today|||52-Week Range 112.09 | +24.85% Year-to-Date |
Investment Objective
The investment seeks to provide investment results that, before fees and expenses, correspond to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index. The fund employs a replication strategy in seeking to track the performance of the S&P Biotechnology Select Industry Index. It generally invests substantially all, but at least 80%, of total assets in the securities comprising the index. The fund may invest in equity securities that are not included in the index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. It is non-diversified.
Latest XBI News
| Biotechnology ETF Investing 101 - ETF News And Commentary May 20 / Zacks.com |
Performance
| 1 month | +2.68% | 3 years | +26.97% | |
| 3 months | +13.96% | 5 years | +13.70% | |
| 1 year | +38.53% | Since inception | +11.63% |
Data through 05/21/2013
Quote Details
| Previous close | $108.69 |
| Open day’s range | 108.55 – 110.22 |
| Net asset value (NAV) | 108.65 (05/20/2013) |
| Daily volume | 141,106 |
| Average volume (3 months) | 225,211 |
Data as of 3:59pm ET, 05/21/2013
Peer Comparisonvs. Health ETFs
| XBI | Category | |
|---|---|---|
| Performance 5-yr return | +13.70% | +13.03% |
| Expense Gross exp ratio | 0.35% | 0.47% |
| Risk 5 year sharpe ratio | 0.65 | 0.75 |
| Net assets | $846.7M | $776.1M |
| Average market cap | $2.9B | $19.4B |
| Average P/E | -- | 21.6 |
| Dividend / Share | -- | 0.22% |
Competitors
| VHT Vanguard Health Care ETF |
| XLV Health Care Select Sector SPDR Fund |
| IXJ iShares S&P Global Healthcare Index Fund |
Holdings
Top 5 SectorsPortfolio weighting
| Healthcare | 100.00% |
| Business service | 0.00% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
Top 10 HoldingsPortfolio weighting
| NPSP NPS Pharmaceuticals Inc | 3.55% |
| VRTX Vertex Pharmaceuticals | 3.16% |
| THRX Theravance, Inc. | 2.96% |
| ALKS Alkermes PLC | 2.91% |
| BIIB Biogen Idec Inc | 2.76% |
| ISIS Isis Pharmaceuticals | 2.75% |
| REGN Regeneron Pharmaceuticals, Inc. | 2.70% |
| SGEN Seattle Genetics, Inc. | 2.59% |
| ACOR Acorda Therapeutics, Inc. | 2.52% |
| AEGR Aegerion Pharmaceuticals, Inc. | 2.47% |